5 min
Endpoints Shorts: Dr. Nadia Sethi on PTC Therapeutics PTC 857 Endpoints
-
- Science
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.
In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less.
Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk about PTC Therapeutics phase 2 trial for PTC 857.
There are currently no treatments to stop or reverse ALS but the ALS Therapy Development Institute is working to change that. To learn more about ALS TDI and our research to end ALS, visit ALS.net
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
Welcome to the latest episode of Endpoints Shorts, presented by the ALS Therapy Development Institute.
In these bite-size podcasts, we’ll be tackling important scientific concepts for people interested in ALS research, current clinical trials, and news from around the ALS space – all in 15 minutes or less.
Our guide throughout this series will be Dr. Nadia Sethi, ALS TDI’s Director of Community Outreach and Engagement. Today, Nadia joins us to talk about PTC Therapeutics phase 2 trial for PTC 857.
There are currently no treatments to stop or reverse ALS but the ALS Therapy Development Institute is working to change that. To learn more about ALS TDI and our research to end ALS, visit ALS.net
Support the show: https://www.als.net/donate/
See omnystudio.com/listener for privacy information.
5 min